Therapeutics announced the appointment of Greg Russotti, Ph.D., as ad-interim Chief Executive Officer, effective April 11, 2023. Dr. Russotti, who has served as the Company’s Chief Technology Officer since January 2020, is succeeding Lalo Flores, Ph.D., who has stepped down as Chief Executive Officer and as a member of the Company’s Board of Directors to pursue other opportunities. In addition, effective April 11, 2023, Michael C. Diem, M.D., was promoted to the role of Chief Financial Officer, and Hy Levitsky, M.D., assumed his prior role as President of Research and Development. The Board of Directors has commenced a search to identify a permanent Chief Executive Officer. Greg Russotti, Ph.D., ad-interim Chief Executive Officer – Prior to joining Century, Dr. Russotti served as Vice President of Cell Therapy Development and Operations at Celgene. Michael Diem, M.D., Chief Financial Officer – Dr. Diem, who joined Century in 2020, most recently served as the Company’s Chief Business Officer. Hy Levitsky, M.D., President of Research and Development – Dr. Levitsky previously served as Century’s President, Research and Development from 2019 until early 2023.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on IPSC:
- Century Therapeutics Announces Leadership Changes
- Century Therapeutics price target lowered to $20 from $23 at BofA
- Century Therapeutics price target lowered to $17 from $19 at H.C. Wainwright
- Century Therapeutics reports FY22 EPS ($2.27), consensus ($2.32)
- Century Therapeutics Reports Full Year 2022 Financial Results and Provides Business Updates
